ADC Therapeutics to Participate in the Jefferies London Healthcare Conference
November 09 2021 - 7:15AM
Business Wire
ADC Therapeutics SA (NYSE: ADCT), a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs) for patients with hematologic malignancies and solid tumors,
announced today that Chris Martin, PhD, Chief Executive Officer,
will participate in a fireside chat at the Jefferies London
Healthcare Conference on Tuesday, November 16th at 11:20 a.m. GMT /
6:20 a.m. EST.
A live webcast of the presentation will be available via the
Events & Presentations page in the Investors section of ADC
Therapeutics’ website, ir.adctherapeutics.com. A replay of the
webcast will be available for approximately 30 days.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage
biotechnology company improving the lives of those affected by
cancer with its next-generation, targeted antibody drug conjugates
(ADCs). The Company is advancing its proprietary PBD-based ADC
technology to transform the treatment paradigm for patients with
hematologic malignancies and solid tumors.
ADC Therapeutics’ CD19-directed ADC ZYNLONTA® (loncastuximab
tesirine-lpyl) is approved by the FDA for the treatment of relapsed
or refractory diffuse large B-cell lymphoma after two or more lines
of systemic therapy. ZYNLONTA is also in development in combination
with other agents. Cami (camidanlumab tesirine) is being evaluated
in a late-stage clinical trial for relapsed or refractory Hodgkin
lymphoma and in a Phase 1b clinical trial for various advanced
solid tumors. In addition to ZYNLONTA and Cami, ADC Therapeutics
has multiple ADCs in ongoing clinical and preclinical
development.
ADC Therapeutics is based in Lausanne (Biopôle), Switzerland and
has operations in London, the San Francisco Bay Area and New
Jersey. For more information, please visit
https://adctherapeutics.com/ and follow the Company on Twitter and
LinkedIn.
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211109005902/en/
Investors Eugenia Litz ADC Therapeutics
Eugenia.Litz@adctherapeutics.com +44 7879 627205
Amanda Hamilton ADC Therapeutics
amanda.hamilton@adctherapeutics.com +1 917-288-7023
EU Media Alexandre Müller Dynamics Group amu@dynamicsgroup.ch
+41 (0) 43 268 3231
USA Media Mary Ann Ondish ADC Therapeutics
maryann.ondish@adctherapeutics.com Tel.: +1 914-552-4625
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Aug 2024 to Sep 2024
ADC Therapeutics (NYSE:ADCT)
Historical Stock Chart
From Sep 2023 to Sep 2024